Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study

Background: Recent knowledge on the key role of interleukin (IL)23/17 axis in psoriasis pathogenesis, led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody specifically targeting IL23. Its efficacy and safety were showed by both clinical trials and real-life experiences. However, real life data on effectiveness and safety of risankizumab in patients who previously failed anti-IL17 are scant. Objectives: To assess the efficacy and safety of risankizumab in patients who previously failed anti-IL17. Methods: A 52-week real-life retrospective study was performed to assess the long-term efficacy and safety of risankizumab in patients who previously failed anti-IL17. Results: A total of 39 patients (26 male,66.7%; mean age 50.5±13.7years) were enrolled. A statistically significant reduction of Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) was assessed at each follow-up (PASI at baseline vs week52: 13.7±5.8 vs 0.9±0.8,p<0.0001; BSA 21.9±14.6 vs 1.9±1.7,p<0.0001). Nail Psoriasis Severity Index improved as well, being statistically significative only at week16 and thereafter [9.3±4.7 at baseline, 4.1±2.4(p<0.01) at week16, 1.4±0.8(p